Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

The primary objective of this study is to better understand patients' attitudes and

experiences during office-based opioid treatment (OBOT) in the COVID-19 pandemic. This

study specifically aims to evaluate attitudes and experiences of people prescribe

buprenorphine across five domains with the hope of evaluating a) whether telemedicine has

improved their access to and experiences with OBOT; b) the factors that motivate

individuals in OBOT to abstain from opioid drug use; c) how patients' view the use of

cannabis, benzodiazepines, and nicotine during OBOT; d) the degree to which patients in

OBOT report using cannabis, benzodiazepines, and nicotine and how their use might have

changed during the COVID-19 pandemic; and e) whether patients attitudes towards cannabis,

benzodiazepines, and cigarettes/e-cigarettes are associated with their use of those same

substances.